Alkem Laboratories

Alkem Laboratories Net Debt per Share

The Net Debt per Share of Alkem Laboratories (ALKEM.NS) as of Nov 20, 2026 is -168.79 INR. In the previous year, Net Debt per Share was -200.49 INR — a change of -15.81% (higher).

Net Debt per Share

-168.79INR

YoY

-15.81%

Last updated:

Net Debt per Share of Alkem Laboratories is 2026 -168.79 INR. Net Debt per Share of Alkem Laboratories was 2025 -200.49 INR. It decreases by -15.81% higher compared to the previous year.

The Alkem Laboratories Net Debt per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt per Share
Date
Net Debt per Share
Jan 1, 2019
24.24 INR
Jan 1, 2020
98.45 INR
Jan 1, 2021
3.20 INR
Jan 1, 2022
113.35 INR
Jan 1, 2023
21.20 INR
Jan 1, 2024
-238.48 INR
Jan 1, 2025
-200.49 INR
Jan 1, 2026
-168.79 INR
The Alkem Laboratories Net Debt per Share history
YEARNet Debt per ShareYoY
-168.79INR-15.81%
-200.49INR-15.93%
-238.48INR-1,224.69%
21.20INR-81.29%
113.35INR+3,440.13%
3.20INR-96.75%
98.45INR+306.09%
24.24INR+286.36%
6.27INR-324.88%
-2.79INR-116.13%
17.30INR-54.51%
38.03INR-39.51%
62.87INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Alkem Laboratories Stock analysis

What does Alkem Laboratories do? Alkem Laboratories Ltd is a leading Indian pharmaceutical company that was founded in 1973 and is headquartered in Mumbai. The company's main business model includes the development, manufacturing, and distribution of pharmaceutical formulations and active ingredients. Alkem Laboratories specializes in generics, branded drugs, and biosimilars, offering a comprehensive range of medical solutions. The company is divided into several divisions, including drug research and development, manufacturing, marketing, and sales. It focuses particularly on chronic diseases such as diabetes, cardiovascular diseases, cancer, neurological disorders, and infectious diseases. Alkem Laboratories employs over 20,000 employees worldwide and aims to improve the health and well-being of people globally. It offers a wide range of both prescription and over-the-counter products, including antibiotics, antifungals, cardiology, gastroenterology, urology, neurology, oncology, psychiatry, dermatology, and pediatrics. The company is committed to developing biosimilars that provide more affordable treatment options for serious diseases such as cancer and autoimmune diseases. It has developed an extensive portfolio of biosimilars, including Rituximab, Trastuzumab, and Adalimumab. Alkem Laboratories has also invested in research and development to create innovative solutions for the healthcare industry. It has established research centers in India, the USA, and Europe to discover new active ingredients, optimize processes, and develop innovative products. The company aims to lead in maintaining the highest quality standards and complying with strict regulatory requirements. Alkem Laboratories has certified facilities in India and the USA according to GMP guidelines. It also has a strong presence in the international pharmaceutical industry community and is a member of organizations such as the International Generic and Biosimilar Medicines Association, the Indian Pharmaceutical Alliance, and the US Pharmaceutical Research and Manufacturers of America. Overall, Alkem Laboratories is characterized by its extensive experience in the pharmaceutical industry and its commitment to the health and well-being of people worldwide. The company strives to create innovative solutions for the medical sector and aims to utilize its cutting-edge technology and expertise to meet the needs of patients globally. Alkem Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alkem Laboratories stock

Net Debt per Share of Alkem Laboratories is -168.79 INR in 2026.

Net Debt per Share of Alkem Laboratories changed from -200.49 INR to -168.79 INR, representing a -15.81% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt per Share Alkem Laboratories since 2006 – with annual values, charts, and detailed analysis.

Net debt per share divides net debt by shares outstanding, showing the debt burden attributable to each share after accounting for cash reserves.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Alkem Laboratories

All Key Metrics — Alkem Laboratories